Decoy Therapeutics (NASDAQ:DCOY) Short Interest Down 51.5% in April

Decoy Therapeutics (NASDAQ:DCOY) was the target of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totaling 11,279 shares, a decrease of 51.5% from the April 15th total of 23,252 shares. Approximately 2.1% of the company’s shares are short sold. Based on an average trading volume of 13,202 shares, the days-to-cover ratio is presently 0.9 days.

Decoy Therapeutics Price Performance

Shares of DCOY stock traded down $0.11 during trading hours on Friday, hitting $4.41. 6,085 shares of the company were exchanged, compared to its average volume of 10,795. The company’s fifty day moving average price is $6.36. Decoy Therapeutics has a 52-week low of $4.32 and a 52-week high of $415.80. The firm has a market cap of $2.34 million, a PE ratio of -0.04 and a beta of 0.38.

Decoy Therapeutics (NASDAQ:DCOY) last issued its quarterly earnings results on Friday, May 8th. The company reported ($4.18) earnings per share (EPS) for the quarter. Research analysts forecast that Decoy Therapeutics will post -12.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DCOY has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Decoy Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. LADENBURG THALM/SH SH began coverage on shares of Decoy Therapeutics in a report on Friday, January 23rd. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Weiss Ratings upgraded shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, May 7th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $30.00.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.